Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Pasqualetti

Showing results (71-80 of 104) with videos related to

Pageof 11
Sort By:
Anticancer Research|December 25, 2016
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal CancerFrancesco Pasqualetti, Sabrina Montrone, Caterina Vivaldi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)Giuseppe Lombardi, Paola Del Bianco, Alba A Brandes, et al.
Acta Neurologica Belgica|August 16, 2021
Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastomaFrancesco Pasqualetti, Nicola Montemurro, Isacco Desideri, et al.
Anticancer Research|May 2, 2018
Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate CancerFrancesco Pasqualetti, Marco Panichi, Aldo Sainato, et al.
Radiation Oncology (London, England)|January 23, 2016
[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary resultsFrancesco Pasqualetti, Marco Panichi, Aldo Sainato, et al.
Neuro-Oncology Practice|May 11, 2026
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approachesAlberto Bosio, Marta Maccari, Marta Padovan, et al.
Journal of Neuro-Oncology|March 10, 2025
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experienceGiulia Cerretti, Alberto Bosio, Giovanni Librizzi, et al.
Oncotarget|May 31, 2018
Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer playersSara Franceschi, Francesca Lessi, Paolo Aretini, et al.
Investigational New Drugs|October 2, 2017
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapyFrancesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, et al.
Future Oncology (London, England)|April 13, 2019
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?Veronica Villani, Alessandra Fabi, Antonio Tanzilli, et al.
Pageof 11

Showing results (71-80 of 104) with videos related to

Sort By:
Pageof 11
Anticancer Research|December 25, 2016
Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal CancerFrancesco Pasqualetti, Sabrina Montrone, Caterina Vivaldi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial)Giuseppe Lombardi, Paola Del Bianco, Alba A Brandes, et al.
Acta Neurologica Belgica|August 16, 2021
Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastomaFrancesco Pasqualetti, Nicola Montemurro, Isacco Desideri, et al.
Anticancer Research|May 2, 2018
Image-guided Stereotactic Body Radiotherapy in Metastatic Prostate CancerFrancesco Pasqualetti, Marco Panichi, Aldo Sainato, et al.
Radiation Oncology (London, England)|January 23, 2016
[(18)F]Choline PET/CT and stereotactic body radiotherapy on treatment decision making of oligometastatic prostate cancer patients: preliminary resultsFrancesco Pasqualetti, Marco Panichi, Aldo Sainato, et al.
Neuro-Oncology Practice|May 11, 2026
Real-world management and long-term outcomes in adolescent, young adult, and adult medulloblastoma: Experience from a monocentric series with multimodal and targeted approachesAlberto Bosio, Marta Maccari, Marta Padovan, et al.
Journal of Neuro-Oncology|March 10, 2025
Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experienceGiulia Cerretti, Alberto Bosio, Giovanni Librizzi, et al.
Oncotarget|May 31, 2018
Cancer astrocytes have a more conserved molecular status in long recurrence free survival (RFS) IDH1 wild-type glioblastoma patients: new emerging cancer playersSara Franceschi, Francesca Lessi, Paolo Aretini, et al.
Investigational New Drugs|October 2, 2017
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapyFrancesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, et al.
Future Oncology (London, England)|April 13, 2019
A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?Veronica Villani, Alessandra Fabi, Antonio Tanzilli, et al.
Pageof 11